2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1575

Serum Vascular Cell Adhesion Molecule-1 (VCAM-1) Levels Are Associated with Vascular Dysfunction and Increased Cardiovascular Risk in an Animal Model and Patients with Rheumatoid Arthritis
Abstract Number: 9

Serum Visfatin Levels in Patients with Axial Spondyloarthitis and Early Rheumatoid Arthritis: Relation to Inflammation and Bone Changes
Abstract Number: 247

Severe Inflammation Following Vaccination Against Streptococcus Pneumoniae in Patients with Cryopyrin-Associated Periodic Syndromes
Abstract Number: 1554

Severe Pneumonia after a 13-Prevalent Pneumonoccal Conjugate Vaccine (Prevena 13) Among Patients with Rheumatoid Arthritis
Abstract Number: 2680

Severity of Morning Stiffness Is Associated More Strongly with Disease Activity in Patients with Rheumatoid Arthritis
Abstract Number: 1592

Sex Differences in Cardiovascular Risk Factors and Event Rates in Patients with Rheumatoid Arthritis – Data from 13 Rheumatology Centers
Abstract Number: 705

Sex Differences in Psoriatic Arthritis: Evaluation of a Real-Life Cohort of 2,118 Italian Patients Treated with Methotrexate
Abstract Number: 1067

Sex Differences in Rates of End-Stage Renal Disease and Death Among Medicaid Patients with Incident Lupus Nephritis
Abstract Number: 84

Sexual Dimorphism in the Association Between Multi-Site Pain and Other Fibromyalgia Features: an Analysis of Data from Three UK Population-Based Studies
Abstract Number: 1211

Shift of Rheumatoid Arthritis Onset Toward Old Age in Japan Based on a Nationwide Cohort Database
Abstract Number: 2235

Shocking? a Systematic Review of Adrenal Insufficiency in Adults on Oral Steroids
Abstract Number: 274

Shrinking Lung Syndrome in Connective Tissue Disease
Abstract Number: 646

Sicca Syndrome in Rheumatoid Arthritis: Is It a Real Sjögren’s?
Abstract Number: 3191

Siglec9 Suppresses Arthritis in Collagen-Induced Mice Model and Inhibits M1 Activation of RAW264.7 Macrophages
Abstract Number: 2179

Signaling By Mammalian Target of Rapamycin (mTORC) Highlight Pathological IgG and IgA in SLE Patients with Secondary APS

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].